aricept
Posted: Thu Oct 27, 2022 4:46 pm
Hi all, I came across this Nature article about Acetyl‑cholinesterase‑inhibitors, and have pasted the abstract below.
The article says that for those with very mild Alzheimers (MMSE about 28), aricept kept MMSE scores stable for almost 6 years. This sounds to me like a convincing reason to start taking aricept at the early MCI stage. Wondering if anyone has an opinion on this? Thank you.
https://www.nature.com/articles/s41598-022-16476-w.pdf
We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall
survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular
dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia
enrolled between 2005 and 2020 by the "Alzheimer’s Disease Research Centers" were analyzed; the
mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating
a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The
MMSE score was almost stable during the frst 6 years of follow up in AChEIs + and then declined,
while in AChEIs− it progressively declined so that at the end of follow-up (13.6 years) the average
decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs+ (p < 0.001). This
trend was driven by LOAD (Δ-MMSE:−10.8 vs. −5.7 points; p < 0.001), although a similar effect was
observed in VD (Δ-MMSE:−11.6 vs. −8.8; p < 0.001). No effect on cognitive status was found in LBD.
At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression)
a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59;
95%CI: 0.53–0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD.
Among older people with dementia, treatment with AChEIs was associated with a slower cognitive
decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the
effectiveness of AChEIs in older patients affected by these types of dementia.
The article says that for those with very mild Alzheimers (MMSE about 28), aricept kept MMSE scores stable for almost 6 years. This sounds to me like a convincing reason to start taking aricept at the early MCI stage. Wondering if anyone has an opinion on this? Thank you.
https://www.nature.com/articles/s41598-022-16476-w.pdf
We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall
survival in a large sample of older patients with late onset Alzheimer’s disease (LOAD), vascular
dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia
enrolled between 2005 and 2020 by the "Alzheimer’s Disease Research Centers" were analyzed; the
mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating
a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The
MMSE score was almost stable during the frst 6 years of follow up in AChEIs + and then declined,
while in AChEIs− it progressively declined so that at the end of follow-up (13.6 years) the average
decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs+ (p < 0.001). This
trend was driven by LOAD (Δ-MMSE:−10.8 vs. −5.7 points; p < 0.001), although a similar effect was
observed in VD (Δ-MMSE:−11.6 vs. −8.8; p < 0.001). No effect on cognitive status was found in LBD.
At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression)
a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59;
95%CI: 0.53–0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD.
Among older people with dementia, treatment with AChEIs was associated with a slower cognitive
decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the
effectiveness of AChEIs in older patients affected by these types of dementia.